Director Dealings

RNS Number : 3482U

Oxford Cannabinoid Tech.Holdings

02 December 2021

 

2 December 2021

Oxford Cannabinoid Technologies Holdings plc

Director Dealings

Oxford Cannabinoid Technologies Holdings plc ("the Company"), announces that it was informed on 1 December 2021 that on 1 December 2021 Clarissa Sowemimo-Coker, the Chief Operating Officer, and Karen Lowe, the Finance Director, had each purchased ordinary shares of £0.01 in the Company ("Ordinary Shares").

Director	Total number of Ordinary Shares purchased	Price per Ordinary Share	Number of Ordinary Shares held following the purchase
Clarissa Sowemimo-Coker	189,594	2.6199 pence	189,594
Karen Lowe	340,010	2.69 pence	340,010

PDMR forms are set out below.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

Oxford Cannabinoid Technologies Holdings plc Dr John Lucas (CEO) Clarissa Sowemimo-Coker (COO)	[phone] [e-mail] [e-mail]
Cairn Financial Advisers Emily Staples Jo Turner	[phone] [phone]
Walbrook PR Limited Paul Vann Nicholas Johnson	[phone] [phone] [e-mail]
Harbor Access LLC Richard Leighton Jonathan Paterson	[e-mail] [phone]

About Oxford Cannabinoid Technologies Holdings Plc :

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market (together the "Group"). Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth.

The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022. The Group's product pipeline also uses a balanced drug product strategy that employs phytocannabinoids, cannabinoid derivatives and other novel compounds for the treatment of pain.

OCTP operates a partnership model with external academic and commercial partners, including the University of Oxford.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Clarissa Sowemimo-Coker
2	Reason for notification
a.	Position/Status	Chief Operating Officer & General Counsel
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Cannabinoid Technologies Holdings plc
b.	LEI	2138005SRWT4998BCE35
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.01 each GB00BMVMRB86
b.	Nature of the transaction	Acquisition of ordinary shares of £0.01 each
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			2.6199 pence	189,594
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	1st December 2021
f.	Place of the transaction	London, UK

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Karen Lowe
2	Reason for notification
a.	Position/Status	Finance Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Cannabinoid Technologies Holdings plc
b.	LEI	2138005SRWT4998BCE35
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.01 each GB00BMVMRB86
b.	Nature of the transaction	Acquisition of ordinary shares of £0.01 each
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			2.69 pence	340,010
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	1st December 2021
f.	Place of the transaction	London, UK

 

END

 

 

DSHQLLBBFLLLFBB